Beijing Aosaikang Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A carries a market capitalization of 12.64B, placing it among publicly traded companies globally. Its enterprise value stands at 10.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beijing Aosaikang Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A has 928.16M shares outstanding.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 53.00. The price-to-sales ratio is 7.39, and the price-to-book ratio stands at 3.92.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 36.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.38B versus a market cap of 12.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.75, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.19, indicating conservative leverage, while an interest coverage ratio of 504.06 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 7.51, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.40, useful for judging operating efficiency across full business cycles. The company generates approximately 2.03M in revenue per employee across its workforce of 846.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.03 indicates how many times Beijing Aosaikang Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A recorded 49.64M in income tax expense. That works out to an effective tax rate of 17.42, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 284.95M, leaving 239.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A's stock has declined approximately 35.88% over the past 52 weeks. The 50-day moving average sits at 12.49, while the 200-day moving average is 14.59.

Over the twelve months ended June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A generated 1.72B in revenue and converted that into 239.18M in net income, yielding earnings per share of 0.25. EBITDA reached 287.50M, while operating income came in at 256.60M.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A holds 2.34B in cash and equivalents against 6.37M in total debt, resulting in a net debt position of -1.19B. Total book value stands at 3.22B, with working capital of 1.76B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A posted a gross margin of 81.69, reflecting its pricing power and cost economics. The operating margin of 14.96 and net profit margin of 13.95 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A paid dividends of 0.09 per share. The dividend payout ratio of 35.96 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Beijing Aosaikang Pharmaceutical Co., Ltd. Class A shareholders.

Beijing Aosaikang Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 31, 2018 with a 10:17 split ratio.

As of June 30, 2026, Beijing Aosaikang Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 9.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.